Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies

Trial Profile

An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Abatacept (Primary) ; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Oct 2018 Planned End Date changed from 30 Sep 2019 to 30 Oct 2019.
    • 30 Oct 2018 Planned primary completion date changed from 30 Sep 2019 to 30 Oct 2019.
    • 07 Aug 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top